Long-Term Clinical Effectiveness of Ustekinumab in Patients With Crohn's Disease: A Retrospective Cohort Study

被引：6

作者：

Ito, Takahiro ^{[1
]}

Maemoto, Atsuo ^{[1
]}

Katsurada, Takehiko ^{[2
]}

Tanaka, Hiroki ^{[3
]}

Motoya, Satoshi ^{[3
]}

Ueno, Nobuhiro ^{[4
]}

Fujiya, Mikihiro ^{[4
]}

Ashida, Toshifumi ^{[1
]}

Hirayama, Daisuke ^{[5
]}

Nakase, Hiroshi ^{[5
]}

机构：

[1] Sapporo Higashi Tokushukai Hosp, IBD Ctr, Sapporo, Hokkaido, Japan

[2] Hokkaido Univ Hosp, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan

[3] Sapporo Kosei Gen Hosp, IBD Ctr, Sapporo, Hokkaido, Japan

[4] Asahikawa Med Univ, Dept Med, Div Gastroenterol & Hematol Oncol, Asahikawa, Hokkaido, Japan

[5] Sapporo Med Univ, Sch Med, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan

来源：

CROHNS & COLITIS 360 | 2020年 / 2卷 / 04期

基金：

日本学术振兴会;

关键词：

clinical effectiveness; ustekinumab; Crohn's disease; positive predictors; MAINTENANCE; SAFETY; INDUCTION; EFFICACY;

D O I：

10.1093/crocol/otaa061

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: This study clarifies the long-term effectiveness of ustekinumab based on real-life data from Japanese Crohn's disease (CD) patients. Methods: A total of 137 patients were included, and 124 patients (90.5%) were exposed to anti-tumor necrosis factor-alpha agents. Results: The clinical remission rate at week 52 was 32.4% in moderate to severely active CD patients. The achievement of clinical remission for 8 weeks after ustekinumab therapy induction was associated with clinical remission at week 52. Ustekinumab persistence rate at week 104 was 81.4%. Conclusion: Ustekinumab is effective and persistent in CD patients with the previous treatment history of several biologics. Lay Summary This is the first study to show the real-world effectiveness and safety of ustekinumab in a large cohort of Crohn's disease (CD) patients in Japan. Ustekinumab is effective and persistent in CD patients previously exposed to several biologics.

引用

页码：1 / 9

页数：9

共 20 条

[1] Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective [J].

Axelrad, Jordan E. ;

Roy, Abhik ;

Lawlor, Garrett ;

Korelitz, Burton ;

Lichtiger, Simon .

WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (46) :10103-10117

[2]

BEST WR, 1976, GASTROENTEROLOGY, V70, P439

[3] Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study [J].

Biemans, Vince B. C. ;

van der Meulen-de Jong, Andrea E. ;

van der Woude, Christine J. ;

Lowenberg, Mark ;

Dijkstra, Gerard ;

Oldenburg, Bas ;

de Boer, Nanne K. H. ;

van der Marel, Sander ;

Bodelier, Alexander G. L. ;

Jansen, Jeroen M. ;

Haans, Jeoffrey J. L. ;

Theeuwen, Rosaline ;

de Jong, Dirk ;

Pierik, Marie J. ;

Hoentjen, Frank .

JOURNAL OF CROHNS & COLITIS, 2020, 14 (01) :33-45

[4] Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial [J].

Colombel, Jean-Frederic ;

Sandborn, William J. ;

Rutgeerts, Paul ;

Enns, Robert ;

Hanauer, Stephen B. ;

Panaccione, Remo ;

Schreiber, Stefan ;

Byczkowski, Dan ;

Li, Ju ;

Kent, Jeffrey D. ;

Pollack, Paul F. .

GASTROENTEROLOGY, 2007, 132 (01) :52-65

[5] Epidemiology and Natural History of Inflammatory Bowel Diseases [J].

Cosnes, Jacques ;

Gower-Rousseau, Corinne ;

Seksik, Philippe ;

Cortot, Antoine .

GASTROENTEROLOGY, 2011, 140 (06) :1785-U118

[6] Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD [J].

Daperno, M ;

D'Haens, G ;

Van Assche, G ;

Baert, F ;

Bulois, P ;

Maunoury, V ;

Sostegni, R ;

Rocca, R ;

Pera, A ;

Gevers, A ;

Mary, JY ;

Colombel, JF ;

Rutgeerts, P .

GASTROINTESTINAL ENDOSCOPY, 2004, 60 (04) :505-512

[7] Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE) [J].

Eberl, Anja ;

Hallinen, Taru ;

af Bjorkesten, Clas-Goran ;

Heikkinen, Markku ;

Hirsi, Eija ;

Kellokumpu, Mikko ;

Koskinen, Inka ;

Moilanen, Veikko ;

Nielsen, Christian ;

Nuutinen, Heikki ;

Suhonen, Ulla-Maija ;

Utriainen, Karri ;

Vihriala, Ilkka ;

Soini, Erkki ;

Wennerstrom, Christina ;

Nissinen, Riikka ;

Borsi, Andras ;

Koivunen, Minni ;

Tillonen, Jyrki ;

Sipponen, Taina .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2019, 54 (06) :718-725

[8] Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease [J].

Feagan, B. G. ;

Sandborn, W. J. ;

Gasink, C. ;

Jacobstein, D. ;

Lang, Y. ;

Friedman, J. R. ;

Blank, M. A. ;

Johanns, J. ;

Gao, L. -L. ;

Miao, Y. ;

Adedokun, O. J. ;

Sands, B. E. ;

Hanauer, S. B. ;

Vermeire, S. ;

Targan, S. ;

Ghosh, S. ;

de Villiers, W. J. ;

Colombel, J. -F. ;

Tulassay, Z. ;

Seidler, U. ;

Salzberg, B. A. ;

Desreumaux, P. ;

Lee, S. D. ;

Loftus, E. V., Jr. ;

Dieleman, L. A. ;

Katz, S. ;

Rutgeerts, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20) :1946-1960

[9] Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial [J].

Hanauer, SB ;

Feagan, BG ;

Lichtenstein, GR ;

Mayer, LF ;

Schreiber, S ;

Colombel, JF ;

Rachmilewitz, D ;

Wolf, DC ;

Olson, A ;

Bao, WH ;

Rutgeerts, P .

LANCET, 2002, 359 (9317) :1541-1549

[10] Early real-world effectiveness of ustekinumab for Crohn's disease [J].

Harris, Richard James ;

McDonnell, Martin ;

Young, David ;

Bettey, Marion ;

Downey, Louise ;

Pigott, Lucinda ;

Felwick, Richard ;

Gwiggner, Markus ;

Cummings, J. R. Fraser .

FRONTLINE GASTROENTEROLOGY, 2020, 11 (02) :111-116

← 1 2 →